Govt Panel Makes This Approval Mandatory For New Drug Licenses
New Delhi: Raising serious regulatory concerns, the apex statutory body under the Central Drugs Standard Control Organisation (CDSCO), the Drugs Consultative Committee (DCC), has cautioned State Licensing Authorities (SLAs) against issuing manufacturing licenses for new drugs without obtaining prior approval from the Central Licensing Authority (CLA).
During its 66th meeting, held on 17th June 2025 in hybrid mode at CDSCO (HQ), FDA Bhawan, New Delhi, the DCC deliberated the agenda in the presence of DCGI Dr. Rajeev Singh Raghuvanshi, who “highlighted the need for strengthening of Drug Regulatory System throughout the country and appreciated the support extended by all the States.”
One of the key agenda items taken up was the issuance of product licenses for new drugs by SLAs without the mandatory approval from the CLA, in violation of regulatory requirements.
Members were apprised that, “As per the rules, the State Licensing Authorities must check the approval, in writing, in favour of the applicant to manufacture drug formulations falling under the purview of new drug as defined in rule 2(w)(iv) of NDCT Rules, 2019, from the Central Licensing Authority (CLA).”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.